12:00 AM
Sep 26, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Eprotirome: Phase III started

Karo Bio began a double-blind, placebo-controlled, international Phase III trial to evaluate eprotirome daily in 630 patients for 2 years. Alkem Laboratories...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >